THERMO FISHER SCIENTIFIC INC. Q1 FY2025 earnings call

Management Statement and Operational Highlights

• Q1 Performance: Thermo Fisher delivered strong Q1 with revenue $10.36 billion, adjusted operating income $2.27 billion, adjusted operating margin 21.9%, and adjusted EPS $5.15 (+1%). Execution across all dimensions was clean.
• Growth Strategy: Three pillars drive growth: high-impact innovation (e.g., Vulcan automated lab, Transcend platform, Olink Reveal kits), trusted partner status (strengthening customer success), and commercial engine.
• Capital Deployment: Announced acquisition of Soventum's purification and filtration business for $4.1 billion, repurchased $1 billion of shares, and increased dividend by 10%.
• PPI Business System: Enabled strong execution, driving share gains, quality, productivity, and customer allegiance, providing a competitive advantage in the macro environment.

Segment Performance

• Life Science Solutions: Q1 reported revenue increased 2% vs prior year, organic revenue growth 2%. Adjusted operating income decreased 1%, margin 35.6%.
• Analytical Instruments: Reported revenue grew 2% y/y, organic revenue growth 3%. Adjusted operating income flat, margin 23.2%.
• Specialty Diagnostics: Reported revenue grew 3% y/y, organic revenue increased 4%. Adjusted operating income increased 3%, margin 26.5%.
• Laboratory Products and Biopharma Services: Reported and organic revenue decreased 1% vs prior year. Adjusted operating income decreased 2%, margin 13%.

Guidance

• Updated 2025 guidance reflects impact of tariffs and US policy changes. Revenue range $43.3 billion to $44.2 billion, adjusted EPS range $21.76 to $22.84. Organic revenue growth expected 1%-3%, adjusted operating income margin 22%-22.6%. Tariffs and policy changes' impacts are factored in, with mitigation actions in place to offset some negatives.

Risks

• Macro Uncertainty: Uncertainty in the macro environment, including tariffs between US and China, which impact revenue and margins.
• US Policy Changes: Impact on academic/government customers and clinical trials, affecting revenue and operating income.
• Foreign Exchange: Fluctuations in foreign exchange rates pose risks to revenue and margin performance.

Question and Answer

Q: Michael Ryskin asked about the guidance range and scenarios for upside/downside.

A: Marc Casper discussed the strong Q1 performance, ongoing mitigation actions to navigate the dynamic macro environment, and optimism about the long-term growth drivers of the industry.

Q: Matt Sykes inquired about manufacturing flexibility.

A: Marc Casper highlighted the PPI business system's role and scale advantages, emphasizing the ability to mobilize quickly and the competitive position enabled by robust manufacturing capabilities across major markets.

Q: Jack Meehan asked about pharmacy tariffs and their impact.

A: Marc Casper talked about leveraging US manufacturing capabilities in pharma services, noting strong demand in fill-finish and drug product areas, and the ongoing efforts to support customers navigating tariff uncertainties.

Q: Rachel Vatnsdal asked about policy changes' impact on academics and CRO.

A: Marc Casper broke down the impact of vaccine-related study cancellations and the expected performance of the academic/government market, noting a soft outlook for the balance of the year but potential improvement based on appropriations dynamics.

Q: Doug Schenkel inquired about market growth rate and M&A.

A: Marc Casper discussed the industry's resilience and long-term drivers, emphasizing the fundamental growth from scientific breakthroughs and healthcare demand, and the company's transparency in updating guidance based on changing views.

Q: Tycho Peterson asked about pharma services and clinical research.

A: Marc Casper talked about biotech's robust performance in clinical research, the company's strong positioning in human trials, and the differentiated capabilities enabling meaningful wins and cost-effectiveness in clinical research